Spinal Muscular Atrophy (SMA) In Vitro Assay Services

Mutations in the SMN1 gene underlie spinal muscular atrophy (SMA), a genetic neurodegenerative condition characterized by motor neuron degeneration, leading to debilitating muscle weakness and atrophy. Despite the absence of a cure, recent advancements in gene therapy, drug discovery, and molecular analysis have yielded significant progress. Creative Biolabs provides a comprehensive suite of advanced in vitro, in vivo, and ex vivo assays, enabling researchers to precisely investigate the complex mechanisms driving SMA pathogenesis.

Available In Vitro Models

Fig.1 SMA induced Neurons.¹

Cell models	Details
SMA Patient-Derived iPSCs	By generating induced pluripotent stem cells (iPSCs) from SMA patient fibroblasts and then directing their differentiation into motor neurons, our researchers create a powerful and personalized disease model. This model, which maintains the patient's specific genetic background, accurately recapitulates the phenotypic characteristics of SMA. It is thus an indispensable tool for both drug discovery and the elucidation of SMA's underlying pathological processes.
3D Tissue-Specific Spinal Cord Culture Model	Our 3D tissue-specific spinal cord culture model offers an unparalleled in vitro platform for SMA research. Utilizing mouse spinal cord slices, we maintain tissue viability for 14 days, preserving the critical 3D architecture and intricate neuron-glial cell interactions found in vivo. This model faithfully replicates local neuronal circuits and neuroblast morphology, providing a near-physiological environment. By enabling the screening of therapeutic compounds in a context that closely mirrors in vivo conditions, our model significantly reduces the risk of failure in subsequent animal experiments and clinical trials.
Spinal Cord Organoid	Spinal cord organoids, generated from pluripotent stem cells (including embryonic stem cells or patient-derived iPSCs), provide a powerful tool for studying SMA. These complex 3D structures, encompassing motor neurons, astrocytes, and other neuronal cell types, faithfully replicate the early neurodevelopmental defects observed in SMA, offering unprecedented insights into disease pathogenesis.

Available SMA In Vitro Services

• Precise SMN Protein Quantification

We offer precise SMN protein quantification in peripheral blood mononuclear cells (PBCs) utilizing advanced imaging flow cytometry and electrochemiluminescence detection. This technology enables sensitive, semi-quantitative analysis, effectively distinguishing functional SMN protein levels. This provides a robust platform for real-time, dynamic monitoring of drug efficacy during SMA therapeutic development.

• SMA High-Throughput Phenotypic Screening Assay Service

Our high-throughput phenotypic screening services offer a versatile suite of detection methods, including fluorescence, luminescence, and color readouts, to accelerate your SMA research. These technologies are adaptable for both array-based and pool-based screening strategies, such as FACS or NGS, and can be seamlessly integrated with cell immunophenotyping. This comprehensive approach ensures a thorough and efficient analysis, providing robust support for your SMA research endeavors.

Click here for more information

For further information regarding the products and services provided, project-specific consultation, and pricing, please submit an inquiry here.

Reference

1. Sierra-Delgado, Julieth Andrea, et al. "In vitro modeling as a tool for testing therapeutics for spinal muscular atrophy and IGHMBP2-related disorders." Biology 12.6 (2023): 867. Distributed under Open Access license CC BY 4.0, without modification.